Results from a 20-year follow-up to the Women’s Health Initiative investigating the long-term influence of menopausal hormone therapy on ovarian and endometrial cancer incidence and mortality were presented by Chlebowski et al at the 2024 ASCO Annual Meeting (Abstract 10506).
